Why Is IDEAYA BIOSCIENCES I (IDYA) Stock Moving Today?
IDEAYA BIOSCIENCES I (IDYA) is drawing unusual attention today. Our newswire has captured 2 stories on IDYA across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 44/100).
Ideaya Biosciences (IDYA) shares fell 9.75% to $27.40. The primary driver of the decline was the company’s announcement of its registrational trial strategy for IDE849, a potential best-in-class DLL3 TOP1 antibody-drug conjugate for neuroendocrine carcinomas.
What Happened
Ideaya Biosciences announced the successful conclusion of a US FDA Type C meeting regarding the Phase 2/3 registrational trial designs for IDE849. The company plans a single-arm extension cohort of approximately 90 refractory gastroenteropancreatic neuroendocrine carcinoma patients to support potential accelerated approval, with the objective response rate by blinded independent central review as the primary endpoint. Additionally, the firm outlined a randomized Phase 3 trial in multiple refractory neuroendocrine carcinoma subtypes. The company also nominated IDE101 as a development candidate for CDKN2A-deficient solid tumors.
What The Data Shows
The stock’s 52-week range is $26.81 to $42.68, and the company printed 28 fresh 52-week lows on November 17, 2026. Ideaya Biosciences has a market capitalization of $3.1 billion and remains unprofitable, with trailing twelve-month earnings per share of -4.52 and revenue down 83.0% over the same period. The stock has a beta of 0.08. In the last 90 days, there were zero insider buys and one sell totaling $985,000, with the most recent transaction on October 8, 2026. CEO Hata Yujiro S sold shares on October 6, 2026. Analysts have recently adjusted their views, with Wedbush adjusting its price target to $63 from $60 and RBC Capital Markets lowering its price target to $45.
What To Watch
Investors will monitor the upcoming November 2026 investor relations events where the company is scheduled to participate.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IDYA by the numbers
The headlines behind the move
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Updates Across MTAP Deletion, PRMT5 and KAT67 Programs - Slideshow
2026-11-19. The following slide deck was published by IDEAYA Biosciences, Inc.
Frequently asked questions
Why is IDYA stock moving today?
IDEAYA BIOSCIENCES I (IDYA) is drawing unusual attention today. Our newswire has captured 2 stories on IDYA across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 44/100). The most recent driver: "Ideaya Biosciences price target lowered to $55 from $62 at JPMorgan" (The Fly).
Is IDYA a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of IDYA coverage reads 44/100 over 2 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is ACCV down today (-18.94%)
- Why is SVRA down today (-17.95%)
- Why is APLD down today (-17.45%)
- Why is AAOI down today (-16.14%)
- Why is CLS down today (-15.03%)
- Why is WOLF down today (-14.70%)
More on IDYA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IDYA move explainers: 2026-11-18 · 2026-11-17